Arovella Therapeutics to Receive US Patent Allowance for Blood Cancer Cell Therapy Platform; Shares Rise 5%

MT Newswires Live

Aug 28, 2025

Arovella Therapeutics (ASX:ALA) has received a Notice of Allowance from the US Patent and Trademark Office for a patent covering its invariant Natural Killer T (iNKT) cell therapy platform to treat blood cancers and solid tumours, according to a Thursday filing with the Australian bourse.

The patent covers the manufacturing of Chimeric Antigen Receptor (CAR)-iNKT cells and once granted will offer protection in the US until at least Feb. 28, 2039, the filing said.

Shares of the company rose 5% in recent Thursday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562706090"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562706090\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562706090?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 11:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562706090","market":"sh","top_or_hot":-1,"title":"Arovella Therapeutics to Receive US Patent Allowance for Blood Cancer Cell Therapy Platform; Shares Rise 5%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ARVEF\">Arovella Therapeutics</a> (ASX:ALA) has received a Notice of Allowance from the US Patent and Trademark Office for a patent covering its invariant Natural Killer T (iNKT) cell therapy platform to treat blood cancers and solid tumours, according to a Thursday filing with the Australian bourse.</p><p>The patent covers the manufacturing of Chimeric Antigen Receptor (CAR)-iNKT cells and once granted will offer protection in the US until at least Feb. 28, 2039, the filing said.</p><p>Shares of the company rose 5% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arovella Therapeutics to Receive US Patent Allowance for Blood Cancer Cell Therapy Platform; Shares Rise 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArovella Therapeutics to Receive US Patent Allowance for Blood Cancer Cell Therapy Platform; Shares Rise 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-28 11:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ARVEF\">Arovella Therapeutics</a> (ASX:ALA) has received a Notice of Allowance from the US Patent and Trademark Office for a patent covering its invariant Natural Killer T (iNKT) cell therapy platform to treat blood cancers and solid tumours, according to a Thursday filing with the Australian bourse.</p><p>The patent covers the manufacturing of Chimeric Antigen Receptor (CAR)-iNKT cells and once granted will offer protection in the US until at least Feb. 28, 2039, the filing said.</p><p>Shares of the company rose 5% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2562706090","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562706090","pubTimestamp":1756353230,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arovella Therapeutics  has received a Notice of Allowance from the US Patent and Trademark Office for a patent covering its invariant Natural Killer T  cell therapy platform to treat blood cancers and solid tumours, according to a Thursday filing with the Australian bourse.The patent covers the manufacturing of Chimeric Antigen Receptor -iNKT cells and once granted will offer protection in the US until at least Feb. 28, 2039, the filing said.Shares of the company rose 5% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4022":"陆运","BK4539":"次新股","BK7096":"制药","CAR.AU":"CAR GROUP LTD","BK4230":"旅客陆运","BK7503":"科技股","LENZ":"Therapeutics","BK7002":"互动媒体与服务","ALA.AU":"AROVELLA THERAPEUTICS LTD","BK4139":"生物科技","CAR":"安飞士"},"translate_title":"Arovella Therapeutics将获得血癌细胞治疗平台的美国专利许可；股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1,"LENZ":1,"CAR.AU":1,"ALA.AU":0.9},"content_text":"Arovella Therapeutics (ASX:ALA) has received a Notice of Allowance from the US Patent and Trademark Office for a patent covering its invariant Natural Killer T (iNKT) cell therapy platform to treat blood cancers and solid tumours, according to a Thursday filing with the Australian bourse.The patent covers the manufacturing of Chimeric Antigen Receptor (CAR)-iNKT cells and once granted will offer protection in the US until at least Feb. 28, 2039, the filing said.Shares of the company rose 5% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}